Zymeworks Wins FDA Approval for Zanidatamab in Biliary Tract Cancer

Vancouver-based Zymeworks (NASDAQ: ZYME; TSX: ZYME) received full FDA approval on October 15, 2026, for zanidatamab — its HER2-targeting bispecific antibody — as a second-line treatment for adults with HER2-amplified biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer. The decision follows the drug’s Priority Review designation and is backed by the pivotal HERIZON-BTC-01 trial, in which zanidatamab delivered an objective response rate of 41.3% in a heavily pre-treated population. This is the company’s first commercial drug approval and marks one of the most significant regulatory milestones for a Canadian-founded biopharmaceutical company in 2026.

The Indication: A Rare But Underserved Population

Biliary tract cancers are diagnosed in approximately 12,000 Americans annually, with HER2 amplification present in roughly 15–20% of BTC cases — creating a targetable patient pool of approximately 1,800–2,400 new U.S. patients per year. Until zanidatamab’s approval, no HER2-directed therapy had received FDA clearance specifically for BTC, leaving oncologists reliant on chemotherapy doublets with limited efficacy. Zanidatamab’s dual HER2 epitope binding mechanism differentiates it from trastuzumab-based regimens by simultaneously blocking HER2 signaling at two distinct domains, a feature Zymeworks argues reduces receptor recycling and sustains tumour suppression longer.

Commercial Opportunity and Competitive Landscape

Analysts at RBC Capital Markets peg the global BTC market at approximately $1.4 billion USD by 2028, with zanidatamab’s peak U.S. sales estimate ranging from $350–$500 million USD annually at full penetration. In CAD terms at today’s USD/CAD rate of 1.4219, that translates to a peak sales ceiling approaching $711 million CAD. Zymeworks’ commercial partner Jazz Pharmaceuticals holds U.S. and European rights following a 2023 licensing deal worth up to $1.76 billion USD in milestones, meaning Zymeworks will collect royalties and milestone payments rather than bearing full commercialization costs. The near-term competitive threat is modest: Roche’s trastuzumab deruxtecan (T-DXd) is approved in HER2-positive breast and gastric cancers but does not carry a BTC label, giving zanidatamab a meaningful first-mover window. Longer term, AstraZeneca and Daiichi Sankyo are running BTC-adjacent HER2 trials that could narrow the gap by 2028.

Stock Reaction and Long-Term Thesis

ZYME shares surged approximately 38% in pre-market trading on October 15, 2026, recovering much of the ground lost during a difficult 2025 for the XBI biotech ETF, which closed Wednesday at $146.77. By contrast, the IBB — which tracks larger-cap biotechs — rose 1.61% on the day, suggesting broader biotech sentiment is supportive but the Zymeworks move is company-specific. The approval converts Zymeworks from a clinical-stage speculation into a royalty-generating commercial entity, which is a meaningful re-rating catalyst for institutional holders who had discounted the stock on binary trial risk.

For long-term investors, the thesis now hinges on two variables: the pace of Jazz’s U.S. launch and the breadth of zanidatamab’s pipeline expansion into HER2-positive gastric and breast cancers, where Phase 3 data are expected in H1 2027. Health Canada has granted zanidatamab Priority Review status domestically, with a Canadian approval decision anticipated by Q1 2027. Canadian retail investors holding ZYME on the TSX should note the stock’s USD-denominated earnings will translate favourably at the current 1.4219 exchange rate, effectively amplifying CAD-denominated returns relative to the underlying USD performance.